|
Boryung is a South Korean pharmaceutical company that develops, manufactures, and markets prescription and over-the-counter medicines. Its business segments include chronic metabolic diseases, specialty care, central nervous system (CNS) disorders, oncology, and renal care. Key products include the Kanarb family for hypertension and dyslipidemia, Trulicity for diabetes, and the Taxotell global business acquired from Sanofi for breast cancer treatment. The company also offers OTC brands such as Gelphos and Yungaksan. Boryung operates manufacturing facilities in Ansan and Yeosu, with the latter holding EU-GMP certification. It serves domestic hospitals, clinics, and pharmacies, and is expanding into global markets through CDMO contracts and international business acquisitions. The company maintains R&D centers in Seoul and Gwanggyo, focusing on new drug development and improved formulations. Summarised from the company's own disclosures, fiscal year ended Jul 2026 |
Industry Drug Manufacturers - General | Homepage boryung.co.kr |
| Sector Healthcare | IR page pharm.boryung.co.kr/ir | |
|
Tags
prescription drugs, over-the-counter drugs, oncology, diabetes, hypertension, renal care, cns disorders, cdmo, generic drugs, branded drugs, Kanarb, Dukarb, Tuvero, Akab, Dukarb Plus, Trulicity, Taxotell, Gelphos, Yungaksan, Yungaksan Cool, Gelphos M, Gelphos L, Zyprexa, Gemzar, Campto, Oxaliplatin, Zeloda, Onvevzi, Genxol, Dacxel, Sampnet, Velkin, Neulasta, Glasgin, L-family, L-Ong, L-Zero, L-Zero Jet
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | ₩ 779.898B |
| Market cap (USD) | $ 573.991M |
| P/E | 6.33 |
| PEG | 0.41 |
| P/BV | 0.87 |
| P/S | 0.74 |
| P/OCF | 5.19 |
| P/FCF | 6.22 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 7.9% |
| ROI | 7.6% |
| ROIC | 7.1% |
| Profit margin | 6.3% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | No |
| Revenue up 3y | Yes |
| Revenue up 5y | Yes |
| Earnings growth 3y (net profit CAGR) | 15.4% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | No |
| Buying back stock | Yes |
| Diluting (TTM) | No |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | — |
| Quality score | 58.8% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.017T | 1.017T | 859.626B | 760.476B | 627.279B | 561.867B | 524.269B | 460.402B | 422.721B | 409.14B | 401.35B | 359.491B | 327.279B |
| Net profit | 64.303B | 69.633B | 40.203B | 41.894B | 43.044B | 26.856B | 32.222B | 20.307B | 56.699B | 5.614B | 20.301B | 21.591B | 14.127B |
| Free cash flow | 110.938B | 67.732B | 27.241B | 7.538B | 44.034B | 26.47B | -20.021B | -15.914B | -87.214B | -15.708B | 899.701M | -6.521B | 18.039B |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (KRW) | 136B | 143B | 131B | 132B | 114B | 117B | 144B | 165B | 194B | 177B |
| ↳ YoY growth | +4.2% | +5.6% | -8.8% | +1.2% | -14.0% | +2.8% | +23.1% | +14.3% | +18.0% | -9.0% |
| ↳ 5y CAGR | +5.6% | +3.7% | -2.7% | -2.9% | +0.1% | +4.7% | +8.0% | +9.2% | ||
| Borrowings, current (KRW) | 1.25B | — | — | — | — | 25.8B | 113B | 50.6B | — | — |
| Borrowings, non-current (KRW) | 0.00 | — | — | — | — | 111B | 94.2B | 152B | 124B | 245B |
| Bonds payable (KRW) | — | — | — | — | — | — | 78B | — | — | 200B |
| Lease liabilities (KRW) | — | 0.00 | 0.00 | 384M | 826M | 757M | 1.13B | 1.9B | 4.25B | 18.9B |
| Cash and deposits (KRW) | 26.3B | 16.4B | 7.62B | 4.52B | 25.5B | 151B | 16.1B | 16.5B | 187B | 228B |
| Intangible assets (KRW) | 17.8B | 17.5B | 17.4B | 15.7B | 55.7B | 92.8B | 184B | 173B | 155B | 144B |
| Right-of-use assets (KRW) | — | — | 0.00 | 891M | 1.32B | 747M | 2.06B | 2.67B | 5.14B | 19.4B |
| Net debt (borrowings + leases - cash) (KRW) | -25.1B | — | — | — | — | -13.1B | 192B | 188B | -59.3B | 35.9B |
| Cash flow detail | ||||||||||
| Operating cash flow (KRW) | 9.36B | -24.3B | 38.9B | 47B | 44.7B | 60.2B | 27.8B | 42.2B | 80.6B | 133B |
| Purchases of property, plant and equipment (KRW) | -25.1B | -63B | -54.8B | -67B | -18.3B | -16.1B | -20.3B | -15B | -12.8B | -22.2B |
| Purchases of intangible assets (KRW) | -1.76B | -4.08B | -2.3B | -1.73B | -38.3B | -43.2B | -103B | -8.33B | -7.22B | -7.7B |
| Change in inventories (cash effect) (KRW) | -26.2B | 7.65B | — | — | — | — | — | — | — | — |
| Change in payables (cash effect) (KRW) | 15.3B | -5.91B | — | — | — | — | — | — | — | — |
| Dividends paid (cash effect) (KRW) | -1.56B | -1.62B | -6.8B | -2.52B | -4.2B | -4.51B | -6.59B | -6.59B | -6.77B | -8.4B |
| Share buybacks (cash effect) (KRW) | -5.13B | -147M | -5B | 0.00 | -5.83B | -4.69B | -188M | 0.00 | 0.00 | — |
| Interest paid (cash effect) (KRW) | -824M | -420M | 0.00 | 0.00 | -2.71B | -4.23B | -5.95B | -9.32B | -9.03B | -10.4B |
| Income taxes paid (cash effect) (KRW) | -8.82B | -31.5B | 862M | -8.24B | -14.3B | -12B | -22.1B | -21.3B | 5.24B | -9.36B |
| Free cash flow (OCF - PPE - intangibles) (KRW) | -17.5B | -91.3B | -18.2B | -21.8B | -11.9B | 850M | -95.2B | 18.9B | 60.5B | 103B |
| Income detail | ||||||||||
| Research and development expense (KRW) | — | — | — | — | — | — | 41.7B | 47.3B | 51.5B | 65.1B |
| Total comprehensive income (KRW) | 6.1B | 55.9B | 18.1B | 29.4B | 25.5B | 44.4B | 48.8B | 37.3B | 67.3B | 69.8B |
| Comprehensive income to owners (KRW) | 6.1B | 56.1B | 18.1B | 29.4B | 25.5B | 44.3B | 48.7B | 37.3B | 67.3B | 69.8B |
| Provision for credit losses (KRW) | -346M | 3.98B | — | — | — | — | — | — | — | — |
| Credit cost ratio (credit losses / average receivables) (%) | 0.3% | 2.9% | — | — | — | — | — | — | — | — |
| Reported | Mar 29, 2019 | Mar 30, 2020 | Aug 14, 2019 | Mar 30, 2020 | Mar 18, 2021 | Mar 11, 2024 | Mar 20, 2025 | Mar 20, 2025 | Mar 20, 2025 | Jul 9, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpDisclosures filed with DART (material events and exchange disclosures), newest first, headlines as filed in Korean. The link opens the filing on DART. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Boryung
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| AVEE | 0.01% | 1,794 | $ 11.73K | Nov 16, 2026 |
| DFEV | 0.01% | 21,171 | $ 141.304K | Nov 12, 2026 |
| DFSE | 0.00% | 3,926 | $ 26.204K | Nov 12, 2026 |
| DFEM | 0.00% | 46,198 | $ 308.345K | Nov 12, 2026 |
| DFAE | 0.00% | 29,565 | $ 197.33K | Nov 12, 2026 |
| DEXC | 0.00% | 743 | $ 4,959.10 | Nov 12, 2026 |
| DFAX | 0.00% | 17,835 | $ 119.039K | Nov 12, 2026 |
| AVEM | 0.00% | 67,616 | $ 442.113K | Nov 16, 2026 |
| AVXC | 0.00% | 199 | $ 1,301.18 | Nov 16, 2026 |

List

